Nascent Biotech Inc. (NBIO) financial statements (2023 and earlier)

Company profile

Business Address 623 17TH STREET, SUITE 4
VERO BEACH, FL 32960
State of Incorp. NV
Fiscal Year End March 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
TTM
3/31/2021
3/31/2020
3/31/2019
3/31/2018
3/31/2017
3/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments213131117130573
Cash and cash equivalents213131117130573
Receivables750750   6060
Other undisclosed current assets     (60)(60)
Total current assets:7527513131117130573
Noncurrent Assets
Other undisclosed noncurrent assets     770828
Total noncurrent assets:     770828
TOTAL ASSETS:75275131311179001,401
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:789637853526203(19)(19)
Accounts payable  8535262031522,339
Other undisclosed accounts payable and accrued liabilities789637   (171)(2,358)
Debt16516250  (60) 
Derivative instruments and hedges, liabilities     04
Due to related parties1501231,28488   
Other undisclosed current liabilities95302693  2452,985
Total current liabilities:1,2001,2242,8796142031662,970
Noncurrent Liabilities
Other undisclosed noncurrent liabilities     (19)(19)
Total noncurrent liabilities:     (19)(19)
Other undisclosed liabilities     1919
Total liabilities:1,2001,2242,8796142031662,970
Stockholders' equity
Stockholders' equity attributable to parent, including:(448)(473)(2,876)(482)(86)734(1,569)
Preferred stock  0    
Common stock1081054533282322
Additional paid in capital17,85917,77413,91712,31911,3509,9548,790
Accumulated deficit(18,415)(18,351)(16,838)(12,833)(11,465)(9,243)(10,380)
Other undisclosed stockholders' equity attributable to parent 0     
Total stockholders' equity:(448)(473)(2,876)(482)(86)734(1,569)
TOTAL LIABILITIES AND EQUITY:75275131311179001,401

Income statement (P&L) ($ in thousands)

12/31/2021
TTM
3/31/2021
3/31/2020
3/31/2019
3/31/2018
3/31/2017
3/31/2016
Revenues750750   3,000 
Cost of revenue
(Cost of Goods and Services Sold)
    (2,000)(333) 
Gross profit:0750  (2,000)2,667 
Operating expenses(829)(681)(615)(1,369)(2,222)(1,573)(4,718)
Other undisclosed operating income (loss)356(1,469)(2,833) 2,000333847
Operating income (loss):(473)(1,400)(3,447)(1,369)(2,222)1,427(3,871)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
426442(557)00(50)(278)
Interest and debt expense142151(87)  145(1,574)
Income (loss) from continuing operations before equity method investments, income taxes:96(807)(4,091)(1,369)(2,221)1,522(5,722)
Other undisclosed income (loss) from continuing operations before income taxes  87  (145) 
Income (loss) from continuing operations before income taxes:96(807)(4,004)(1,369)(2,221)1,377(5,722)
Income tax expense     (240) 
Net income (loss):96(807)(4,004)(1,369)(2,221)1,137(5,722)
Other undisclosed net income (loss) attributable to parent(142)(151)  (0) 1,574
Net income (loss) available to common stockholders, diluted:(47)(959)(4,004)(1,369)(2,222)1,137(4,149)

Comprehensive Income ($ in thousands)

12/31/2021
TTM
3/31/2021
3/31/2020
3/31/2019
3/31/2018
3/31/2017
3/31/2016
Net income (loss):96(807)(4,004)(1,369)(2,221)1,137(5,722)
Comprehensive income (loss), net of tax, attributable to parent:96(807)(4,004)(1,369)(2,221)1,137(5,722)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: